Skip to main content

Bicycle Therapeutics plc (BCYC) Stock Forecast

Data as of Aug 6, 2026

Healthcare · Current price $3.96 (-0.38%)

Consensus Target
$10.67
Upside
+176.8%
Analysts
5
Rating
Buy(2.40)

Price Target Range

Low $8.00Consensus $10.67High $12.00
▲ Current $3.96

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

BCYC vs Sector & Market

MetricBCYCHealthcare AvgLarge Cap Avg
Analyst Rating2.402.252.42
Analyst Count5818
Target Upside+176.8%+16316.0%+17.2%
P/E Ratio-1.483.4135.26

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$5M$7M$9M4
2026-12-31$4M$7M$8M5
2027-03-31$58M$86M$111M3
2027-06-30$65M$97M$125M3
2027-09-30$73M$109M$140M3
2027-12-31$82M$123M$158M3

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$-0.66$-0.48$-0.273
2026-12-31$-0.60$-0.44$-0.254
2027-03-31$-0.83$-0.61$-0.342
2027-06-30$-0.83$-0.61$-0.342
2027-09-30$-0.85$-0.62$-0.352
2027-12-31$-0.88$-0.64$-0.362

Frequently Asked Questions

What is the analyst consensus for BCYC?

The consensus among 5 analysts covering Bicycle Therapeutics plc (BCYC) is Buy with an average price target of $10.67.

What is the highest price target for BCYC?

The highest analyst price target for BCYC is $12.00.

What is the lowest price target for BCYC?

The lowest analyst price target for BCYC is $8.00.

How many analysts cover BCYC?

5 analysts have issued ratings for Bicycle Therapeutics plc in the past 12 months.

Is BCYC a buy or sell right now?

Based on 5 analyst ratings, BCYC has a consensus rating of Buy (2.40/5) with a +176.8% upside to the consensus target of $10.67.

What are the earnings estimates for BCYC?

Analysts estimate BCYC will report EPS of $-0.48 for the period ending 2026-09-30, with revenue estimated at $7M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.